Chou Associates Management Inc. maintained its position in shares of Sanofi (NYSE:SNY) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 410,000 shares of the company’s stock at the end of the 2nd quarter. Sanofi accounts for about 6.1% of Chou Associates Management Inc.’s holdings, making the stock its 7th largest holding. Chou Associates Management Inc.’s holdings in Sanofi were worth $19,717,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Harbour Capital Advisors LLC acquired a new stake in Sanofi in the 1st quarter worth $113,000. Parallel Advisors LLC grew its position in Sanofi by 42.5% in the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC grew its position in Sanofi by 33.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after purchasing an additional 776 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its position in Sanofi by 142.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after purchasing an additional 2,098 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its position in Sanofi by 95.8% in the 1st quarter. Proficio Capital Partners LLC now owns 4,265 shares of the company’s stock worth $210,000 after purchasing an additional 2,087 shares during the last quarter. Institutional investors own 9.33% of the company’s stock.
Several research firms have issued reports on SNY. Cowen and Company restated a “market perform” rating and issued a $52.00 price target (up from $46.00) on shares of Sanofi in a research report on Tuesday, August 1st. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Argus restated a “buy” rating and issued a $55.00 price target on shares of Sanofi in a research report on Friday, September 1st. Zacks Investment Research lowered shares of Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Sanofi currently has a consensus rating of “Hold” and a consensus target price of $53.50.
Shares of Sanofi (NYSE SNY) traded down 0.08% during mid-day trading on Friday, hitting $50.57. 1,776,344 shares of the stock traded hands. The company’s 50 day moving average is $49.17 and its 200 day moving average is $47.96. The firm has a market capitalization of $127.01 billion, a P/E ratio of 11.74 and a beta of 0.87. Sanofi has a one year low of $36.81 and a one year high of $50.65.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting analysts’ consensus estimates of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi’s quarterly revenue was down 2.3% on a year-over-year basis. On average, equities analysts expect that Sanofi will post $3.33 EPS for the current fiscal year.
In other Sanofi news, major shareholder Sanofi purchased 105,820 shares of the stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average cost of $482.04 per share, with a total value of $51,009,472.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by company insiders.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.